**Name of Journal: *World Journal of Gastrointestinal Su******rgery***

**Manuscript NO: 47711**

**Manuscript Type: REVIEW**

**Use of absorbable meshes in laparoscopic paraesophageal hernia repair**

Quesada BM *et al*.Absorbable mesh in paraesophageal hernia repair

Bernabé M Quesada, Adelina E Coturel

**Bernabé M Quesada, Adelina E Coturel,** Department of Surgery, Cosme Argerich Hospital, Buenos Aires ZC 1155, Argentina

**ORCID number:** Bernabé M Quesada (0000-0002-3094-0031); Adelina E Coturel (0000-0001-5379-6872).

**Author contributions:** Quesada BM and Coturel AE designed and performed the research, and analyzed the data; Quesada BM wrote the paper.

**C****o****nflict-of-interest statement:** The authors declare they have no conflicts of interest.

**O****p****e****n****-****A****ccess:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Bernabé M Quesada, MD,** **Assistant Professor, Attending Doctor,** Department of Surgery, Cosme Argerich Hospital, Alte Brown 240, Buenos Aires ZC 1155, Argentina. bmquesada@hotmail.com

**T****elephone: +**54-11-48942061

**Fax:** +54-11-48942061

**Received:** March 21, 2019

**Peer-review started:** March 22, 2019

**First decision:** August 2, 2019

**Revised:** September 30, 2019

**Accepted:** October 14, 2019

**Article in press:**

**Published online:**

**Abstract**

Paraesophageal hernia (PEH) repair is one of the most challenging upper gastrointestinal operations. Its high rate of recurrence is due mostly to the low quality of the crura and size of the hiatal defect. In an attempt to diminish the recurrence rates, some clinical investigators have begun performing mesh-reinforced cruroplasty with nonabsorbable meshes like polypropylene or polytetrafluoroethylene. The main problem with these materials is the occurrence, in some patients, of serious mesh-related morbidities, such as erosions into the stomach and the esophagus, some of which necessitate subsequent esophagectomy or gastrectomy. Absorbable meshes can be synthetic or biological and were introduced in recent years for PEH repair with the intent of diminishing the recurrence rates observed after primary repair alone but, theoretically, without the risks of morbidities presented by the nonabsorbable meshes. The current role of absorbable meshes in PEH repair is still under debate, since there are few data regarding their long-term efficacy, particularly in terms of recurrence rates, morbidity, need for revision, and quality of life. In this opinion review, we analyze all the presently available evidence of reinforced cruroplasty for PEH repair using nonabsorbable meshes (synthetic or biological), focusing particularly on recurrence rates, mesh-related morbidity, and long-term quality of life.

**Key words:** Paraesophageal hernia; Laparoscopy; Mesh; Absorbable; Biological

**©****T****h****e****A****u****t****h****o****r****(****s****)****2****0****1****9****.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Paraesophageal hernia repair is one of the most challenging laparoscopic operations. This type of hernia is large and frequently associated with a short esophagus and poor quality of the diaphragmatic crura. Different types of mesh have been used to lower recurrence rates but many of them, mostly nonabsorbable, have been associated with significant morbidity (*i.e*., erosions). In this paper, we discuss the use of absorbable meshes (synthetic and biologic) in paraesophageal hernia repair.

Quesada BM, Coturel AE. Use of absorbable meshes in laparoscopic paraesophageal hernia repair. *World J Gastrointest Surg* 2019; In press

**INTRODUCTION**

There are four types of hiatal hernias (HHs). Type I (sliding HH) are the most common, and their surgical indication is usually for gastroesophageal reflux disease (GERD). Types II [true paraesophageal hernia (PEH)]; fundus herniation with an abdominal esophagogastric junction), III (fundus and esophagogastric herniation) and IV (fundus, esophagogastric junction as well as another abdominal organ, such as colon) are usually referred as PEHs. The PEHs are uncommon, accounting for only 5%-10% of HHs, but with more than 90% of them being type III.

The proper management of PEH is controversial and even their surgical indication is now under debate. Historically, all PEHs were operated because of a higher complication rate observed after conservative treatment. Today, their management has shifted to a case-by-case decision, since the risk of the repair can be high in elderly patients with multiple comorbidities and the risk of complications (according to observation) seems to be lower than in the historical reports[1].

One of the main problems of laparoscopic PEH repair is a high recurrence rate - being 12%-42% in some large series[2], while other series have shown up to 60%[3]. To improve these results, some clinical investigators began to use prosthetic materials to reinforce the crural closure. The first mesh-reinforced cruroplasties used nonabsorbable materials like polypropylene or polytetrafluoroethylene (PTFE)[4]. The occurrence of serious morbidity, in some patients, after the nonabsorbable mesh placement (*i.e*., erosions into the stomach or the esophagus, some of which required esophagectomy or gastrectomy) has kept the use of these materials from becoming standard[5-7].

The ideal mesh material should be able to help reduce tension of the crural closure, without causing erosion or dysphagia, and with provision of long-term duration. This ideal material has not yet been found.

Absorbable meshes were introduced to maintain the theoretical benefit of reducing the recurrence rate without the associated morbidity of the nonabsorbable materials. They can be synthetic, such as Vicryl® (Ethicon, Somerville, NJ, United States) or Bio-A® (Gore Medical, Newark, DE, United States), or biological, such as Surgisis® (Cook Medical, Bloomington, IN, United States), AlloDerm® (Allergan PLC, Dublin, Ireland), or StratticeTM (Allergan PLC) (Table 1). Although they seem to be safe, with very low short- and long-term morbidity rates, the main questions regarding their applicability are long-term efficacy and, in some cases (biological), their high costs.

A recent survey, conducted by the Society of American Gastrointestinal Endoscopic Surgeons (known as SAGES) and answered by more than 2500 members, revealed that among surgeons using mesh for HH repair, 67% preferred absorbable material. Among the high-volume surgeons (> 20 cases of PEH repair per year), 23% reported using mesh reinforcement in the majority of their cases, while the remaining 77% of surgeons reported using it in approximately half of their cases[8]. PEH repairs continue to be so controversial that a clinical guideline for the management of HH concluded that there is not sufficient evidence to support or to speak against the use of mesh to reinforce crural closure[9].

We conducted a thorough search of the Medline and PubMed databases that would allow us to discuss the various results published by different groups worldwide, using all kinds of absorbable meshes for laparoscopic PEH repair.

**EXPERIENCES WITH ABSORBABLE SYNTHETIC MESHES**

One of the first publications of crural reinforcement with an absorbable mesh (Bio-A®) described work by Massullo *et al*[10]. This initial experience consisted of only 11 patients with GERD or PEH. All patients received a reinforced laparoscopic cruroplasty with Bio-A® mesh, after which they underwent either Nissen or Toupet fundoplication. Mean follow-up was 13 mo, with 1 case of recurrence (9%) and no mesh-related complications (MRCs). The clinical value of this initial experience was limited, however, because of the small number of patients and the short follow-up.

A later prospective series of 70 patients, consisting of 48 PEH and 22 large type I HH, was published in 2013 by Powell and coworkers[11]. The crural reinforcement was also performed with Bio-A® mesh but without the classical U-shape. Instead, the investigators cut the mesh only to cover the crural closure, in an attempt to make no contact with the dissected esophagus. On short-term follow-up, there were no MRCs.

Iossa *et al*[12] recently published a retrospective series reporting their mid-term results on 120 patients with Bio-A® mesh-reinforced cruroplasty. Mean follow-up was 42 mo, and recurrence rates were 5.4% in the obese group and 7.1% in the nonobese population. No MRCs were recorded. The value of this paper is limited, however, since most of the patients were obese and having undergone concomitant bariatric surgery (sleeve gastrectomy) and the rest of the patients having been operated because of GERD, with only 6 cases representing PEH. Nevertheless, the study showed that mesh placement was safe, with no MRCs, and recurrence rate was low.

Asti *et al*[13] published a retrospective experience of 100 cases of reinforced cruroplasty with Bio-A® mesh, after which all patients received a Toupet fundoplication. The indications for mesh placement were weak or frail crura and large HH (90% of the cases were PEH). No MRCs were observed and the recurrence rate was 9%, with a mean follow-up of 30 mo, and mostly in patients with type III PEH. Although this is a retrospective series, it has the value of showing the safety of Bio-A® mesh placement with a low recurrence rate in the mid-term. Other small retrospective series have yielded similar results[14,15].

Zehetner and coworkers[16] published their experience with reinforced cruroplasty using polyglactin mesh (Vycril®) secured with a biological glue (BioGlue® surgical adhesive; CryoLife Inc, Kennesaw, GA, United States). This material has a degradation time between 6 wk and 8 wk. Of the 35 patients with an intrathoracic stomach (defined as > 50% of the stomach inside the thoracic cavity), 21 completed a 1-year follow-up, at which point they were evaluated by esophagogram, pH monitoring, and upper endoscopy. The recurrence rate was 9.5% (2 cases; 1 having GERD symptoms and 1 being asymptomatic). No MRCs were observed. These different experiences are summarized in Table 2.

**EXPERIENCES WITH ABSORBABLE BIOLOGIC MESHES**

Oelschlager *et al*[17] published, in 2006, a multicenter prospective and randomized trial, comparing suture alone *vs* reinforced cruroplasty with Surgisis® for the treatment of PEH. A total of 108 patients with symptomatic large PEH were enrolled, 51 in the Surgisis arm and 57 in the suture-alone arm. All demographic and PEH type distributions were similar among both groups. At 6-mo follow-up, there was a significant improvement in all the symptoms that had been described in the preoperative period. The majority of patients (90%) underwent an upper gastrointestinal contrast study, the data from which showed a statistically significant difference in recurrence rate in favor of the Surgisis group (24% *vs* 9% respectively). On multivariate analysis, the only factor associated with a lower risk of recurrence was the placement of Surgisis®.

The long-term follow-up of this experience[17] was published in 2011. Of the original 108 patients, the investigators were able to contact 72, now with a median follow-up of 58 mo. No differences were observed between the two groups in terms of frequency or severity of upper gastrointestinal symptoms. Recurrence rates were 59% in the suture-alone group and 54% in the Surgisis group. The conclusion of the study is that the initial advantage for the use of biologic reinforcement of the cruroplasty was erased in long-term follow-up (5 years). However, the high recurrence rate observed in this experience might be biased by the fact that the diagnosis was made only by experienced radiologists and any herniation into the hiatal space was considered as a recurrence. The responses on quality of life (QOL) questionnaires remained satisfactory[18].

Lee *et al*[19] from the Nebraska University retrospectively reviewed their experience with reinforced cruroplasty with AlloDerm® mesh. This material is biologic and is supposed to be fully incorporated in the recipient tissue at 9 mo postapplication. The study evaluated 52 patients, with a median follow-up of 16 mo. No MRCs were observed, and the recurrence rate was 3.8%.

A more recent experience from the same group consisted of a retrospective review of their experience with 35 patients who submitted to reinforced cruroplasty with StratticeTM mesh. All patients had PEH at least of 5 cm on upper endoscopy, with a mean hernia size of 10 cm. At a short follow-up of 12 mo, 5 recurrences were observed (14%). The investigators concluded that the use of this mesh was safe, producing short-term results similar to those of other comparable materials[20].

In a study designed to identify factors associated with PEH recurrence after reinforced cruroplasty with biologic material, Lidor and coworkers[21] from Johns Hopkins University found that the risk of recurrence was higher in patients with intrathoracic stomach. The material used in this study was the Veritas mesh (Baxter International, Deerfield, IL, United States) and the recurrence rate was 27% at 1-year follow-up, with most of the patients reporting a better QOL despite recurrence. No MRCs were reported. At 36 mo, most patients reported overall satisfaction but symptoms such as heartburn, early satiety and nausea remained as in the preoperative period. The investigators’ conclusion was that, despite a high recurrence rate, most of the patients remained asymptomatic and reported ‘good’ on QOL questionnaires. These different experiences using biological meshes are summarized in Table 3.

**EXPERIENCES COMPARING MULTIPLE MATERIALS**

Tam *et al*[22] retrospectively reviewed 795 patients, of which 106 received crural mesh reinforcement, with 84% of the cases receiving a biological mesh. The recurrence rate was similar between both groups. This might be explained by the fact that most patients requiring mesh placement were older and had bigger hernias with poor quality crura, with some even having a completely intrathoracic stomach. Three patients (2.8%) had MRCs. Two patients suffered from a severe fibrosis around a biological mesh causing dysphagia, with one requiring several endoscopic dilatations and the other esophagectomy. One patient suffered a cardiac tamponade that required sternotomy and right coronary artery hemostasis, due to a tacker injury. The investigators recommend selective use of mesh cruroplasty.

Parsak *et al*[23] published an interesting prospective and randomized trial comparing crural reinforcement with polypropylene *vs* polyglactin mesh in patients operated for GERD. A total of 150 patients were included in the study (75 receiving polypropylene and 75 receiving polyglactin). Postoperative morbidity was similar for both groups, with no MRCs. At a mean follow-up period of approximately 36 mo, the recurrence rate was 7.5%, similar between both arms of the study. No erosion was reported in any group.

Zehetner *et al*[24] published in 2011 a retrospective evaluation comparing open *vs* laparoscopic PEH repair. In this experience, they used multiple mesh materials (Surgisis®, Vycril®, and Bio-A®) and the recurrence rate was 18%, similar between the open and laparoscopic approach groups, with the latter being superior in terms of shorter hospital stay and reduced morbidity.

An interesting prospective and randomized trial was conducted by Watson *et al*[26]. They compared suture cruroplasty (43 cases) *vs* reinforced cruroplasty with absorbable mesh (41 cases receiving Surgisis®) and nonabsorbable mesh (42 cases receiving TiMESH (PFM Medical Titanium gmbh, Nürnberg, Germany) in patients with large PEH. No differences were observed in term of recurrence between the three arms of the study and - as seen in most of the other studies previously cited in this review - most were asymptomatic. A limitation of this study is its short follow-up of only 12 mo, since this duration might not allow for detection of late recurrences and late complications of nonabsorbable meshes (*i.e*., erosion)[25]. A later evaluation of QOL performed on these patients at 24-mo follow-up showed no differences between the groups.

Jones *et al*[27] published, in 2015, one of the few papers reporting on long-term follow-up of reinforced cruroplasty with the use of an absorbable mesh. Most large hernias in this study were operated using biological material (AlloDerm® and StratticeTM), whereas synthetic material (Bio-A®) was used mostly for the smaller ones. No MRC was observed. At 5 years after surgery, radiologic recurrence was 39%, but most of the preoperative symptoms were significantly better in the postoperative period.

Finally, a recent meta-analysis by Huddy *et al*[28], evaluating results of suture-alone cruroplasty *vs* absorbable mesh-reinforced cruroplasty *vs* nonabsorbable mesh-reinforced cruroplasty found that the addition of the mesh significantly reduces recurrence rate, with more benefits being obtained with the nonabsorbable material. The rate of surgical revisions was also significantly reduced with the addition of a mesh. There were no reports of erosions in the study, probably because of a short-term follow-up. These different experiences using multiple materials are summarized in Table 4.

**CONCLUSION**

Laparoscopic crural reinforcement with absorbable material (synthetic or biological) is becoming accepted by the surgical community, as has been revealed by a large survey conducted by SAGES. This event is probably related more to their safety profiles (few MRCs reported) instead of their long-term recurrence rates. More studies with longer follow-up periods are needed to clarify this. The actual evidence shows, however, that despite high recurrence rates, most patients remain asymptomatic, with good QOL, and very few require surgical revisions.

**REFERENCES**

1 **Stylopoulos N,** Rattner DW. Paraesophageal hernia: when to operate? *Adv Surg* 2003; **37**: 213-229 [PMID: 12953635 DOI: 10.1097/00000658-200210000-00012]

2 **Hashemi M**, Peters JH, DeMeester TR, Huprich JE, Quek M, Hagen JA, Crookes PF, Theisen J, DeMeester SR, Sillin LF, Bremner CG. Laparoscopic repair of large type III hiatal hernia: objective followup reveals high recurrence rate. *J Am Coll Surg* 2000; **190**: 553-60; discussion 560-1 [PMID: 10801022]

3 **Dallemagne B**, Kohnen L, Perretta S, Weerts J, Markiewicz S, Jehaes C. Laparoscopic repair of paraesophageal hernia. Long-term follow-up reveals good clinical outcome despite high radiological recurrence rate. *Ann Surg* 2011; **253**: 291-296 [PMID: 21217518 DOI: 10.1097/SLA.0b013e3181ff44c0]

4 **Kuster GG**, Gilroy S. Laparoscopic technique for repair of paraesophageal hiatal hernias. *J Laparoendosc Surg* 1993; **3**: 331-338 [PMID: 8268502]

5 **Tatum RP**, Shalhub S, Oelschlager BK, Pellegrini CA. Complications of PTFE mesh at the diaphragmatic hiatus. *J Gastrointest Surg* 2008; **12**: 953-957 [PMID: 17882502]

6 **Griffith PS**, Valenti V, Qurashi K, Martinez-Isla A. Rejection of goretex mesh used in prosthetic cruroplasty: a case series. *Int J Surg* 2008; **6**: 106-109 [PMID: 18234570 DOI: 10.1016/j.ijsu.2007.12.004]

7 **Stadlhuber RJ**, Sherif AE, Mittal SK, Fitzgibbons RJ Jr, Michael Brunt L, Hunter JG, Demeester TR, Swanstrom LL, Daniel Smith C, Filipi CJ. Mesh complications after prosthetic reinforcement of hiatal closure: a 28-case series. *Surg Endosc* 2009; **23**: 1219-1226 [PMID: 19067074 DOI: 10.1007/s00464-008-0205-5]

8 **Pfluke JM**, Parker M, Bowers SP, Asbun HJ, Daniel Smith C. Use of mesh for hiatal hernia repair: a survey of SAGES members. *Surg Endosc* 2012; **26**: 1843-1848 [PMID: 22274928 DOI: 10.1007/s00464-012-2150-6]

9 Guidelines for the management of hiatal hernia A SAGES guideline. Available from: http://www.sages.org/publications/guideline/guide-lines-for-the-management-of-hiatal-hernia

10 **Massullo JM**, Singh TP, Dunnican WJ, Binetti BR. Preliminary study of hiatal hernia repair using polyglycolic acid: trimethylene carbonate mesh. *JSLS* 2012; **16**: 55-59 [PMID: 22906331 DOI: 10.4293/108680812X13291597715943]

11 **Powell BS**, Wandrey D, Voeller GR. A technique for placement of a bioabsorbable prosthesis with fibrin glue fixation for reinforcement of the crural closure during hiatal hernia repair. *Hernia* 2013; **17**: 81-84 [PMID: 22581201 DOI: 10.1007/s10029-012-0915-4]

12 **Iossa A**, Silecchia G. Mid-term safety profile evaluation of Bio-A absorbable synthetic mesh as cruroplasty reinforcement. *Surg Endosc* 2019; [PMID: 30675663 DOI: 10.1007/s00464-019-06676-3]

13 **Asti E**, Sironi A, Bonitta G, Lovece A, Milito P, Bonavina L. Crura augmentation with Bio-A® mesh for laparoscopic repair of hiatal hernia: single-institution experience with 100 consecutive patients. *Hernia* 2017; **21**: 623-628 [PMID: 28396955 DOI: 10.1007/s10029-017-1603-1]

14 **Berselli M**, Livraghi L, Latham L, Farassino L, Rota Bacchetta GL, Pasqua N, Ceriani I, Segato S, Cocozza E. Laparoscopic repair of voluminous symptomatic hiatal hernia using absorbable synthetic mesh. *Minim Invasive Ther Allied Technol* 2015; **24**: 372-376 [PMID: 26220614 DOI: 10.3109/13645706.2015.1064446]

15 **Priego Jiménez P**, Salvador Sanchís JL, Angel V, Escrig-Sos J. Short-term results for laparoscopic repair of large paraesophageal hiatal hernias with Gore Bio A® mesh. *Int J Surg* 2014; **12**: 794-797 [PMID: 24947948 DOI: 10.1016/j.ijsu.2014.06.001]

16 **Zehetner J**, Lipham JC, Ayazi S, Oezcelik A, Abate E, Chen W, Demeester SR, Sohn HJ, Banki F, Hagen JA, Dickey M, Demeester TR. A simplified technique for intrathoracic stomach repair: laparoscopic fundoplication with Vicryl mesh and BioGlue crural reinforcement. *Surg Endosc* 2010; **24**: 675-679 [PMID: 19690911 DOI: 10.1007/s00464-009-0662-5]

17 **Oelschlager BK**, Pellegrini CA, Hunter J, Soper N, Brunt M, Sheppard B, Jobe B, Polissar N, Mitsumori L, Nelson J, Swanstrom L. Biologic prosthesis reduces recurrence after laparoscopic paraesophageal hernia repair: a multicenter, prospective, randomized trial. *Ann Surg* 2006; **244**: 481-490 [PMID: 16998356]

18 **Oelschlager BK**, Pellegrini CA, Hunter JG, Brunt ML, Soper NJ, Sheppard BC, Polissar NL, Neradilek MB, Mitsumori LM, Rohrmann CA, Swanstrom LL. Biologic prosthesis to prevent recurrence after laparoscopic paraesophageal hernia repair: long-term follow-up from a multicenter, prospective, randomized trial. *J Am Coll Surg* 2011; **213**: 461-468 [PMID: 21715189 DOI: 10.1016/j.jamcollsurg.2011.05.017]

19 **Lee YK**, James E, Bochkarev V, Vitamvas M, Oleynikov D. Long-term outcome of cruroplasty reinforcement with human acellular dermal matrix in large paraesophageal hiatal hernia. *J Gastrointest Surg* 2008; **12**: 811-815 [PMID: 18181005 DOI: 10.1007/s11605-007-0463-x]

20 **Lomelin D**, Smith A, Bills N, Chiruvella A, Crawford C, Krause C, Bayer R, Oleynikov D. Long-Term Effectiveness of Strattice in the Laparoscopic Closure of Paraesophageal Hernias. *Surg Innov* 2017; **24**: 259-263 [PMID: 28492357 DOI: 10.1177/1553350617693520]

21 **Lidor AO**, Steele KE, Stem M, Fleming RM, Schweitzer MA, Marohn MR. Long-term quality of life and risk factors for recurrence after laparoscopic repair of paraesophageal hernia. *JAMA Surg* 2015; **150**: 424-431 [PMID: 25785415 DOI: 10.1001/jamasurg.2015.25]

22 **Tam V**, Luketich JD, Levy RM, Christie NA, Awais O, Shende M, Nason KS. Mesh cruroplasty in laparoscopic repair of paraesophageal hernias is not associated with better long-term outcomes compared to primary repair. *Am J Surg* 2017; **214**: 651-656 [PMID: 28826953 DOI: 10.1016/j.amjsurg.2017.06.011]

23 **Parsak CK**, Erel S, Seydaoglu G, Akcam T, Sakman G. Laparoscopic antireflux surgery with polyglactin (vicryl) mesh. *Surg Laparosc Endosc Percutan Tech* 2011; **21**: 443-449 [PMID: 22146169 DOI: 10.1097/SLE.0b013e31823acc87]

24 **Zehetner J**, Demeester SR, Ayazi S, Kilday P, Augustin F, Hagen JA, Lipham JC, Sohn HJ, Demeester TR. Laparoscopic versus open repair of paraesophageal hernia: the second decade. *J Am Coll Surg* 2011; **212**: 813-820 [PMID: 21435915 DOI: 10.1016/j.jamcollsurg.2011.01.060]

25 **Watson DI**, Thompson SK, Devitt PG, Smith L, Woods SD, Aly A, Gan S, Game PA, Jamieson GG. Laparoscopic repair of very large hiatus hernia with sutures versus absorbable mesh versus nonabsorbable mesh: a randomized controlled trial. *Ann Surg* 2015; **261**: 282-289 [PMID: 25119120 DOI: 10.1097/SLA.0000000000000842]

26 **Koetje JH**, Irvine T, Thompson SK, Devitt PG, Woods SD, Aly A, Jamieson GG, Watson DI. Quality of Life Following Repair of Large Hiatal Hernia is Improved but not Influenced by Use of Mesh: Results From a Randomized Controlled Trial. *World J Surg* 2015; **39**: 1465-1473 [PMID: 25651955 DOI: 10.1007/s00268-015-2970-3]

27 **Jones R**, Simorov A, Lomelin D, Tadaki C, Oleynikov D. Long-term outcomes of radiologic recurrence after paraesophageal hernia repair with mesh. *Surg Endosc* 2015; **29**: 425-430 [PMID: 25030473 DOI: 10.1007/s00464-014-3690-8]

28 **Huddy JR**, Markar SR, Ni MZ, Morino M, Targarona EM, Zaninotto G, Hanna GB. Laparoscopic repair of hiatus hernia: Does mesh type influence outcome? A meta-analysis and European survey study. *Surg Endosc* 2016; **30**: 5209-5221 [PMID: 27129568 DOI: 10.1007/s00464-016-4900-3]

**P-Reviewer:** Grawish ME, Vagholkar KR

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Argentina

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Different types of absorbable meshes**

|  |  |  |
| --- | --- | --- |
| **Type of material** | **Composition** | **Commercial name** |
| Synthetic | Polyglactin 910 | Vycril® |
| Synthetic | Polyglycolic acid (67%)Trimethylene carbonate (33%) | Bio-A® |
| Biological | Porcine small intestine submucosa | Surgisis® |
| Biological | Acellular human dermis | AlloDerm® |
| Biological | Bovine pericardium collagen matrix | Veritas® |
| Biological | Porcine acellular dermal collagen | Permacol®1  |
| Biological | Porcine-derived acellular dermal matrix | StratticeTM |

1Medtronic, Minneapolis, MN, United States.

**Table 2 Experiences with absorbable synthetic mesh**

| **Publication** | **Study design** | ***n*** | **Type of mesh** | **Recurrence** | **MRC** | **Median FU in mo** |
| --- | --- | --- | --- | --- | --- | --- |
| Massullo *et al*[10] | Retrospective | 11 | Bio-A® | 9% | No | 13 |
| Iossa *et al*[12] | Retrospective | 120 | Bio-A® | 7.1% | No | 42 |
| Asti *et al*[13] | Retrospective | 100 | Bio-A® | 9% | No | 30 |
| Zehetner *et al*[16] | Retrospective | 35 | Vicryl® | 9.5% | No | 12 |

FU: Follow-up; MRC: Mesh-related complication.

**Table 3 Experiences with biological mesh**

| **Author** | **Study design** | ***n*** | **Type of Mesh** | **Recurrence** | **MRC** | **Median FU in mo** |
| --- | --- | --- | --- | --- | --- | --- |
| Oelschlager *et al*[17] | RCT | 108 (51 with mesh) | Surgisis® | 9% | No | 6 |
| Oelschlager *et al*[18] | RCT | 72 (33 with mesh) | Surgisis® | 54% | No | 58 |
| Lee *et al*[19] | Retrospective | 52 | AlloDerm® | 3.8% | No | 16 |
| Lomelin *et al*[20] | Retrospective | 35 | StratticeTM | 14% | No | 12 |
| Lidor *et al*[21] | Prospective non-randomized | 111 | Veritas® | 27% | No | 36 |

FU: Follow-up; MRC: Mesh-related complication; RCT: Randomized-controlled trial.

**Table 4 Experiences with multiple mesh materials**

| **Author** | **Study design** | ***n*** | **Type of mesh** | **Recurrence** | **MRC** | **Median FU in mo** |
| --- | --- | --- | --- | --- | --- | --- |
| Tam *et al*[22]  | Retrospective | 106 | Mostly biological  | 22% | 2.8% | NS |
| Parsak *et al*[23] | RCT | 150 | 75 Polypropylene/75 Polyglactin | 7.5% | No | 36 |
| Watson *et al*[25] | RCT | 126 | 43 Suture alone41 Surgisis®42 Nonabsorbable  | Similar, about 20% | No | 12 |

FU: Follow-up; NS: Not stated; RCT: Randomized-controlled trial.